24-649 Phase I
A Phase 1a/1b Study of the pan-KRAS Inhibitor LY4066434 in Participants with KRAS Mutant Solid Tumors
Search Cancer Clinical Trials
Mass General Cancer Center offers patients access to a wide variety of clinical trials of promising new therapies. Use the search tool to find open protocols for your type of cancer.
100 results
24-514 Phase I
A Phase 1a/1b Study of the PI3Ka:RAS Breaker BBO-10203 in Subjects with Advanced Solid Tumors (The BREAKER-101 Trial)
22-173 Phase I
A Phase 1a/1b Study to Evaluate the Safety and Tolerability of STK-012 as a Single Agent and in Combination Therapy in Subjects With Selected Advanced Solid Tumors
23-392 Phase I
A Phase 1a/1b, Dose-Escalation/Dose-Expansion study of NPX267 in Subjects with Solid Tumors Known to Express HHLA-2
22-458 Phase I
A Phase 1b Study of JNJ-75276617 in Combination with AML Directed Therapies for Participants with Acute Myeloid Leukemia Harboring KMT2A or NPM1 Alterations
23-369 Phase I
A Phase 1b, Open-Label Study of Elranatamab in combination with Carzfilzomib plus Dexamethasone and Elranatmab in combination with PF-0790180 in Participants with relapsed refractory Multiple Myeloma
22-448 Phase II
A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study to Determine the Safety and Efficacy of BGB-11417 as Monotherapy, in Combination With Dexamethasone, Dexamethasone/Carfilzomib, Dexamethasone/Daratumumab, and Dexamethasone/Pomalidomide in Patients With Relapsed/Refractory Multiple Myeloma and t(11;14)
24-143 Phase II
A Phase 1b/2 Open-Label Study of Disitamab Vedotin Monotherapy or in Combination with Other Anti-Cancer Therapies in Solid Tumors
22-008 Phase II
A phase 1b/2 study of onvansertib in combination with paclitaxel in triple-negative metastatic breast cancer patients
22-166 Phase II
A Phase 1B/2, Open Label Umbrella Study of Elranatamab (PF-06863135), A B-CELL Maturation Antigen (BCMA) CD3 Bispecific Antibody, In Combination with Other Anti-Cancer Treatments in Participants with Multiple Myeloma
Showing 61 - 70 of 100 results